Corresponding Author: Daria Szkwarko, DO, MPH, 111 Brewster St, Pawtucket, RI 02860 (Szkwarkd@gmail.com).
Published Online: January 19, 2023. doi:10.1001/jama.2022.24362
Conflict of Interest Disclosures: None reported.
Funding/Support: Dr Szkwarko was partially supported by Institutional Development Award Number U54GM115677 from the National Institute of General Medical Sciences of the NIH, which funds Advance Clinical and Translational Research. Dr Kim was supported by NIH/NIAID under R25AI140490 Emerging Infectious Disease Scholars Program at Brown University.
Role of the Funder/Sponsor: The funders had no role in the preparation, review, or approval of the manuscript and decision to submit the manuscript for publication.
Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, Advance-CTR, or Emerging Infectious Disease Scholars.
Additional Contributions: All authors contributed equally. The authors would like to thank John Bernardo, MD (Massachusetts Department of Public Health), who did not receive compensation, for his support in formalizing this article.
TR , Njie
G , Zenner
et al. Guidelines for the treatment of latent tuberculosis infection. MMWR Recomm Rep
. 2020;69(1):1-11. PubMedGoogle ScholarCrossref
Latent Tuberculosis Infection. Centers for Disease Control and Prevention; 2020.
TR , Villarino
ME , Borisov
et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med
. 2011;365(23):2155-2166.PubMedGoogle ScholarCrossref
International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis. Bull World Health Organ
. 1982;60(4):555-564.PubMedGoogle Scholar